Abstract:The incretin hormones, glucose-dependent insulinotropic polypeptide (GIP) and glucagonlike peptide-1 (GLP-1), which are secreted by cells of the gastrointestinal tract in response to meal ingestion, exercise important glucoregulatory effects, including the glucose-dependent potentiation of insulin secretion by pancreatic β-cells. Research on the defective incretin action in type 2 diabetes mellitus suggests that the observed loss of insulinotropic activity may be due primarily to a decreased responsiveness of β-cells to GIP. GLP-1 does retain efficacy, albeit not at physiologic levels. Accordingly, augmentation of GLP-1 is a logical therapeutic strategy to ameliorate this deficiency, although the short metabolic half-life of the native hormone renders direct infusion impractical. GLP-1 receptor agonists that resist degradation by the enzyme dipeptidyl peptidase-4 (DPP-4) and have protracted-action kinetics have been developed, and DPP-4 inhibitors that slow the enzymatic cleavage of native GLP-1 provide alternative approaches to enhancing incretin-mediated glucose control. However, GLP-1 receptor agonists and DPP-4 inhibitors are premised on highly divergent mechanisms of action. DPP-4 is ubiquitously expressed in many tissues and is involved in a wide range of physiologic processes in addition to its physiologic influence on incretin hormone biological activity. GLP-1 receptor agonists provide a pharmacologic level of GLP-1 receptor stimulation, whereas DPP-4 inhibitors appear to increase levels of circulating GLP-1 to within the physiologic range. This article examines the physiology of the incretin system, mechanistic differences between GLP-1 receptor agonists and DPP-4 inhibitors used as glucose-lowering agents in the treatment of type 2 diabetes, and the implications of these differences for treatment. The results of recent head-to-head trials are reviewed, comparing the effects of incretin-based therapies on a range of clinical parameters, including glycemia, β-cell function, weight, and cardiovascular function.

Anti-diabetic actions of glucagon-like peptide-1 on pancreatic beta-cells

Dipeptidyl Peptidase IV(DPP IV): a Novel Emerging Target for the Treatment of Type 2 Diabetes

Multiple Factors Related to the Secretion of Glucagon-Like Peptide-1

Protective effects of glucagon-like polypeptide 1(GLP-1),GLP-1 mimetics and dipeptidyl peptidase IV on pancreatic function

Effect of glucagon-like peptide-1 for the treatment of diabetes mellitus

Progress of extrapancreatic effects by glucagon-like peptide-1

GLP1-derived nonapeptide GLP1(28-36)amide protects pancreatic β-cells from glucolipotoxicity

GLP-1, a powerful physiological incretin: an update.

Glucagon-like Peptide 1 and Its Derivatives in the Treatment of Diabetes-preclinical and Clinical Results

GLP-1 Receptor Agonists: Beyond Their Pancreatic Effects

The physiology of glucagon-like peptide 1

New insight into the mechanisms underlying the function of the incretin hormone glucagon-like peptide-1 in pancreatic β-cells: the involvement of the Wnt signaling pathway effector β-catenin

Hepatic function of glucagon-like peptide-1 and its based diabetes drugs

Control of insulin secretion by GLP-1

Molecular Mechanism of Glucagon-like Peptide 1 and Its Analogies Regulating the Proliferation of Β Cells

The clinical experience of GLP-1 receptor agonist drugs

Activation of the GLP-1 receptor signalling pathway: a relevant strategy to repair a deficient beta-cell mass

Pharmacological Effects of EGLP-1, a Novel Analog of Glucagon-Like Peptide-1, on Carbohydrate and Lipid Metabolism

New anti-diabetic agents-DPP-4 inhibitors: Viewing the advance of treatment for T2DM from pancreatic α-cells

Incretin-based therapies for type 2 diabetes mellitus: properties, functions, and clinical implications

Research Progress of Glucagon-Like Peptide-1 in the Treatment of Type 2 Diabetes Mellitus